January 24, 2018
January 24, 2018
24 January 2018 - The Scientific Founder of Lion TCR, Prof. Antonio Bertoletti and collaborators won the SingHealth Duke-NUS Research Award 1st Prize 2018 on SingHealth Duke-NUS Research Day 2018. The Award is a recognition and celebration of the outstanding and invaluable contributions by the team to the biomedical research landscape in SingHealth Duke-NUS Academic Medical Centre (AMC).
Title and abstract of the award-winning research:
Personalized T cell therapy against HBV related hepatocellular carcinoma
Abstract: The efficacy of cancer T-cell immunotherapy is increasingly recognized. We developed a method to select T-cell receptors (TCR) from HBV-specific T-cells of patients who resolved HBV infection and reintroduce them on lymphocytes of hepatocellular carcinoma (HCC) patients. Our objective was to test whether HBV-specific TCR-redirected T-cells recognize HCC with HBV-DNA integration and can be used in immunotherapy against HCC. We profiled the HBV transcripts in HCC with HBV-DNA integration in order to select the HBV-specific TCR able to redirect T-cells against them. These engineered T-cells lysed HCC cells in vitro and in animal models. The approach was then translated in a clinical setting. Primary HCC of a patient treated with liver transplantation was analyzed for HBV-transcript expression. We detected HBV-mRNA coding for a fragment of HBV-envelope containing an epitope recognized by a HLA-B58-restricted HBV-specific TCR. The patient (HLA-B58+) developed HCC relapses in the lung and was treated with multiple infusions of the HLA-B58-restricted TCR-redirected T-cells. An objective positive response was observed while new lesions in the lung or liver have not been detected till date. In conclusion, we demonstrate that immunotherapy of HBV-related HCC is possible and the HBV integration profile in HCC can guide personalized treatment of HCC patients.
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List
Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma
Scientific Founder, Prof Antonio Bertoletti Appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre
Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells
Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.
Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient